Company news
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) news
Tevogen Bio Holdings Inc. news releases on 6ix. Latest, Jan 28, 2025: Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
Press releases — page 3
Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
January 27, 2025
Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach
January 26, 2025
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
January 23, 2025
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
January 22, 2025
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference
December 25, 2024
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
December 22, 2024
Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda
December 18, 2024
Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy
November 25, 2024
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
November 18, 2024
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations
November 7, 2024
Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support
November 3, 2024
Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs
October 30, 2024
Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity
October 28, 2024
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID
October 10, 2024
Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
August 21, 2024
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
August 14, 2024
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
July 10, 2024
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
June 24, 2024
Tevogen Bio Set to Join Russell 3000® Index
June 11, 2024
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
June 10, 2024
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
June 6, 2024
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
June 5, 2024
Tevogen Bio Reports First Quarter 2024 Financial Results
May 28, 2024
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
May 15, 2024
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
May 9, 2024
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
April 30, 2024
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
April 2, 2024
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
March 27, 2024
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
March 19, 2024
Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN
February 13, 2024
Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation
June 28, 2023